101 related articles for article (PubMed ID: 1311286)
21. Low expression of CD20 and CD23 in Epstein-Barr virus-induced B cell tumors in SCID/hu mice.
Garnier JL; Cooper NR; Cannon MJ
Am J Pathol; 1993 Feb; 142(2):353-8. PubMed ID: 7679547
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus interactions with human lymphocyte subpopulations: virus adsorption, kinetics of expression of Epstein-Barr virus-associated nuclear antigen, and lymphocyte transformation.
Menezes J; Jondal M; Leibold W; Dorval G
Infect Immun; 1976 Feb; 13(2):303-10. PubMed ID: 177360
[TBL] [Abstract][Full Text] [Related]
23. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2/CD23 and low levels of the EBV receptor CR2.
Billaud M; Busson P; Huang D; Mueller-Lantzch N; Rousselet G; Pavlish O; Wakasugi H; Seigneurin JM; Tursz T; Lenoir GM
J Virol; 1989 Oct; 63(10):4121-8. PubMed ID: 2550660
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the human IgE receptor (Fc epsilonRII/CD23) by Epstein-Barr virus (EBV): Ku autoantigen binds specifically to an EBV-responsive enhancer of CD23.
Shieh B; Schultz J; Guinness M; Lacy J
Int Immunol; 1997 Dec; 9(12):1885-95. PubMed ID: 9466316
[TBL] [Abstract][Full Text] [Related]
26. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
[TBL] [Abstract][Full Text] [Related]
27. Activation and immortalization of leukaemic B cells by Epstein-Barr virus.
Walls EV; Doyle MG; Patel KK; Allday MJ; Catovsky D; Crawford DH
Int J Cancer; 1989 Nov; 44(5):846-53. PubMed ID: 2555307
[TBL] [Abstract][Full Text] [Related]
28. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus.
Ernberg I; Falk K; Minarovits J; Busson P; Tursz T; Masucci MG; Klein G
J Gen Virol; 1989 Nov; 70 ( Pt 11)():2989-3002. PubMed ID: 2479717
[TBL] [Abstract][Full Text] [Related]
29. Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes.
Rochford R; Hobbs MV; Garnier JL; Cooper NR; Cannon MJ
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):352-6. PubMed ID: 8380497
[TBL] [Abstract][Full Text] [Related]
30. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.
Gavioli R; De Campos-Lima PO; Kurilla MG; Kieff E; Klein G; Masucci MG
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5862-6. PubMed ID: 1321426
[TBL] [Abstract][Full Text] [Related]
31. Synergy between human immunodeficiency virus type 1 and Epstein-Barr virus in T lymphoblastoid cell lines.
Zhang RD; Guan M; Park Y; Tawadros R; Yang JY; Gold B; Wu B; Henderson EE
AIDS Res Hum Retroviruses; 1997 Jan; 13(2):161-71. PubMed ID: 9007201
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA.
Dillner J; Kallin B; Ehlin-Henriksson B; Timar L; Klein G
Int J Cancer; 1985 Mar; 35(3):359-66. PubMed ID: 2982749
[TBL] [Abstract][Full Text] [Related]
33. Complex formation of CD23/surface immunoglobulin and CD23/CD81/MHC class II on an EBV-transformed human B cell line and inferable role of tetraspanin.
Kijimoto-Ochiai S; Noguchi A; Ohnishi T; Araki Y
Microbiol Immunol; 2004; 48(5):417-26. PubMed ID: 15215629
[TBL] [Abstract][Full Text] [Related]
34. Infection of the HTLV-I-harbouring T-lymphoblastoid line MT-2 by Epstein-Barr virus.
Koizumi S; Zhang XK; Imai S; Sugiura M; Usui N; Osato T
Virology; 1992 Jun; 188(2):859-63. PubMed ID: 1316683
[TBL] [Abstract][Full Text] [Related]
35. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G
Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus gene expression in nasopharyngeal carcinoma.
Young LS; Dawson CW; Clark D; Rupani H; Busson P; Tursz T; Johnson A; Rickinson AB
J Gen Virol; 1988 May; 69 ( Pt 5)():1051-65. PubMed ID: 2836550
[TBL] [Abstract][Full Text] [Related]
38. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1.
Wrightham MN; Stewart JP; Janjua NJ; Pepper SD; Sample C; Rooney CM; Arrand JR
Virology; 1995 Apr; 208(2):521-30. PubMed ID: 7538250
[TBL] [Abstract][Full Text] [Related]
39. Analysis of transformation with Epstein-Barr virus and phenotypic characteristics of lymphoblastoid cell lines established from patients with hairy cell leukemia.
Sairenji T; Spiro RC; Reisert PS; Paquin L; Sakamoto K; Shibuya A; Sullivan JL; Katayama I; Humphreys RE
Am J Hematol; 1983 Dec; 15(4):361-74. PubMed ID: 6316777
[TBL] [Abstract][Full Text] [Related]
40. MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.
Lee SP; Wallace LE; Mackett M; Arrand JR; Searle PF; Rowe M; Rickinson AB
Int Immunol; 1993 May; 5(5):451-60. PubMed ID: 8391306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
